Log In
Print
BCIQ
Print
Print this Print this
 

larazotide (AT-1001, SPD550)

  Manage Alerts
Collapse Summary General Information
Company Alba Therapeutics Corp.
DescriptionTight junction regulator
Molecular Target Zonulin receptor
Mechanism of ActionZonulin receptor antagonist
Therapeutic ModalityPeptide
Latest Stage of DevelopmentPhase II
Standard IndicationCeliac disease
Indication DetailsTreat celiac disease
Regulatory Designation

U.S. - Fast Track (Treat celiac disease)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today